Product Description
Erlogem 100/150 (Erlotinib) is a chemotherapeutic agent available in form of tablets for oral administration.
Generic Name- Erlotinib
Drug Class- Antineoplastic agent
Erlotinib is a tyrosine kinase receptor inhibitor used in the management of some types of non-small cell lung cancer and advanced pancreatic cancer. It acts by selectively and reversibly inhibiting the tyrosine kinase activity of epidermal growth factor receptors which are involved in cancer cell proliferation, apoptosis, angiogenesis, invasions and metastasis.
Erlogem 100/150 (Erlotinib) is a chemotherapeutic agent available in form of tablets for oral administration.
Erlotinib is indicated for:
Erlotinib Monotherapy | |
Erlotinib | 150 mg/day |
GEM-ERL (Gemcitabine plus Erlotinib) Regimen | |
Erlotinib | 100 mg/day |
Gemcitabine | 1000 mg/m2 weekly for the
first 3 weeks in a 4-week cycle |
Dosage Forms and Strengths
Adverse Reactions
are anorexia, fatigue, dyspnea, rash, cough, diarrhea, nausea, vomiting and infection
Contraindications
At Admac we aim at providing innovative World-Standard medicines for all, at affordable prices. Admac is fully committed towards WHO standards; quality & growth, latest technology & R & D with sheer hard work and dedicated team work.